Home LiteratureArticle Details
PMID: 29898992 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG

Abstract

Purpose: In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates tumor-associated draining lymph nodes (DLN), affects adaptive immune responses and combinatorial efficacy of radiotherapy with immune checkpoint blockade (ICB).Experimental Design: We developed a preclinical model to compare stereotactic radiotherapy (Tumor RT) with or without ENI to examine immunologic differences between radiotherapy techniques that spare or irradiate the DLN.Results: Tumor RT was associated with upregulation of an intratumoral T-cell chemoattractant chemokine signature (CXCR3, CCR5-related) that resulted in robust infiltration of antigen-specific CD8+ effector T cells as well as FoxP3+ regulatory T cells (Tregs). The addition of ENI attenuated chemokine expression, restrained immune infiltration, and adversely affected survival when combined with ICB, especially with anti-CLTA4 therapy. The combination of stereotactic radiotherapy and ICB led to long-term survival in a subset of mice and was associated with favorable CD8 effector-to-Treg ratios and increased intratumoral density of antigen-specific CD8+ T cells. Although radiotherapy technique (Tumor RT vs. ENI) affected initial tumor control and survival, the ability to reject tumor upon rechallenge was partially dependent upon the mechanism of action of ICB; as radiotherapy/anti-CTLA4 was superior to radiotherapy/anti-PD-1.Conclusions: Our results highlight that irradiation of the DLN restrains adaptive immune responses through altered chemokine expression and CD8+ T-cell trafficking. These data have implications for combining radiotherapy and ICB, long-term survival, and induction of immunologic memory. Clinically, the immunomodulatory effect of the radiotherapy strategy should be considered when combining stereotactic radiotherapy with immunotherapy. Clin Cancer Res; 24(20); 5058-71. ©2018 AACR.

MeSH Terms
Adoptive Transfer Animals Cell Line, Tumor Combined Modality Therapy Cytokines/metabolism Disease Models, Animal Humans Immunotherapy/methods Lymph Nodes/immunology,metabolism,pathology,radiation effects Lymphocytes, Tumor-Infiltrating/immunology,metabolism,pathology Melanoma, Experimental Mice Neoplasms/immunology,metabolism,pathology,therapy Prognosis Radiosurgery/methods T-Cell Antigen Receptor Specificity T-Lymphocyte Subsets/immunology,metabolism Xenograft Model Antitumor Assays
Chemicals
Cytokines
Authors & Affiliations
21 authors, click to expand affiliations / ORCID
Marciscano Ariel E
Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ghasemzadeh Ali
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nirschl Thomas R
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Theodros Debebe
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kochel Christina M
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Francica Brian J
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Muroyama Yuki
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Anders Robert A
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. | Department of Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sharabi Andrew B
Department of Radiation Medicine and Applied Sciences, University of California, San Diego, Moores Cancer Center, San Diego, California.
Velarde Esteban
Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mao Wendy
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Chaudhary Kunal R
Department of Radiation Oncology, Columbia University Medical Center, New York, New York.
Chaimowitz Matthew G
Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Wong John
Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Selby Mark J
Bristol-Myers Squibb Company, Redwood City, California.
Thudium Kent B
Bristol-Myers Squibb Company, Redwood City, California.
Korman Alan J
Bristol-Myers Squibb Company, Redwood City, California.
Ulmert David
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Thorek Daniel L J
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. | Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
DeWeese Theodore L
Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. | Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Drake Charles G
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. cgd2139@cumc.columbia.edu. | Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
References (47)
47 references, click to expand
  1. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9 PMID: 23462419
  2. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Oncotarget. 2016 Jul 12;7(28):43039-43051 PMID: 27343548
  3. IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.
    Am J Pathol. 2013 Jun;182(6):2345-54 PMID: 23583648
  4. Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
    J Exp Med. 2011 Sep 26;208(10):1989-2003 PMID: 21930769
  5. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
    Cancer Immunol Res. 2013 Jul;1(1):32-42 PMID: 24777248
  6. Mitotic progression following DNA damage enables pattern recognition within micronuclei.
    Nature. 2017 Aug 24;548(7668):466-470 PMID: 28759889
  7. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  8. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
    Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):571-9 PMID: 26867885
  9. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.
    Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9967-72 PMID: 26216968
  10. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Clin Lung Cancer. 2014 Jul;15(4):287-93 PMID: 24594401
  11. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Nature. 2015 Apr 16;520(7547):373-7 PMID: 25754329
  12. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
    Nat Commun. 2015 Jun 25;6:7458 PMID: 26109379
  13. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    J Exp Med. 2013 Aug 26;210(9):1695-710 PMID: 23897981
  14. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.
    Nat Rev Cancer. 2015 Jul;15(7):409-25 PMID: 26105538
  15. In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model.
    Clin Cancer Res. 2017 Sep 15;23(18):5502-5513 PMID: 28606922
  16. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
    Cancer Cell. 2017 May 8;31(5):711-723.e4 PMID: 28486109
  17. High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities.
    Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1591-9 PMID: 18640502
  18. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
    Cancer Immunol Res. 2017 Nov;5(11):992-1004 PMID: 28970196
  19. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.
    J Immunol. 2008 Mar 1;180(5):3132-9 PMID: 18292536
  20. Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2016 Mar 1;22(5):1161-72 PMID: 26490306
  21. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Immunity. 2014 Nov 20;41(5):843-52 PMID: 25517616
  22. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Clin Cancer Res. 2013 Oct 15;19(20):5626-35 PMID: 23983257
  23. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.
    Oncoimmunology. 2014 Apr 25;3:e28518 PMID: 25071979
  24. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
    J Exp Med. 2011 Sep 26;208(10):2005-16 PMID: 21930765
  25. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.
    Cancer Immunol Immunother. 2014 Mar;63(3):259-71 PMID: 24357146
  26. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice.
    J Immunol. 2013 Jan 15;190(2):812-20 PMID: 23248265
  27. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells.
    J Immunol. 2005 Dec 15;175(12):8200-8 PMID: 16339559
  28. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
    Cancer Immunol Res. 2016 Jul;4(7):621-630 PMID: 27241845
  29. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.
    Cancer Res. 2011 Apr 1;71(7):2488-96 PMID: 21300764
  30. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
    Nat Commun. 2017 Jun 09;8:15618 PMID: 28598415
  31. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy.
    Cancer Res. 2010 Apr 1;70(7):2697-706 PMID: 20215523
  32. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
    PLoS One. 2016 Jun 09;11(6):e0157164 PMID: 27281029
  33. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    J Exp Med. 2009 Aug 3;206(8):1717-25 PMID: 19581407
  34. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92 PMID: 26576711
  35. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo.
    J Immunol. 2001 May 15;166(10):6099-103 PMID: 11342628
  36. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Cancer Immunol Res. 2015 Apr;3(4):345-55 PMID: 25527358
  37. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.
    J Immunol. 2004 Aug 15;173(4):2462-9 PMID: 15294960
  38. Radiation enhances regulatory T cell representation.
    Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35 PMID: 21093169
  39. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors.
    J Bacteriol. 2002 Aug;184(15):4177-86 PMID: 12107135
  40. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.
    J Immunol. 2008 Sep 1;181(5):3099-107 PMID: 18713980
  41. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
    Br J Cancer. 2013 May 28;108(10):2063-9 PMID: 23591198
  42. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Cancer Res. 2013 May 1;73(9):2782-94 PMID: 23418320
  43. Small portable interchangeable imager of fluorescence for fluorescence guided surgery and research.
    Technol Cancer Res Treat. 2015 Apr;14(2):213-20 PMID: 24354756
  44. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.
    J Biol Chem. 1998 Mar 6;273(10):5858-68 PMID: 9488723
  45. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
    J Exp Med. 2006 May 15;203(5):1259-71 PMID: 16636135
  46. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
    Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1052-63 PMID: 26581142
  47. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
    J Immunol. 2005 Jun 15;174(12):7516-23 PMID: 15944250
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
Published
2018-00-15
Epub
2018-00-13
Pages
5058-5071
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC6532976
Subset
IM
Grants
NCI NIH HHS · R01 CA201035 · United States
NCI NIH HHS · R01 CA154555 · United States
NCI NIH HHS · P30 CA006973 · United States
NCI NIH HHS · R01 CA127153 · United States
NCI NIH HHS · L30 CA231829 · United States
NIGMS NIH HHS · T32 GM007309 · United States
NIGMS NIH HHS · T32 GM136577 · United States
NCI NIH HHS · P30 CA008748 · United States
NCATS NIH HHS · KL2 TR001444 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com